The nonstaff members of IAS–USA Viral Hepatitis Advisory Board are volunteers and are not compensated for their role in overseeing the program. Listed below are the IAS–USA Viral Hepatitis Advisory Board members and their financial relationships with commercial interests within the past 12 months from the date of disclosure.


Members

Andrew I. Aronsohn, MD
Associate Professor of Medicine
The University of Chicago Medicine
Chicago, Illinois

Dr Aronsohn has no relevant financial affiliations to disclose. (Updated 11/19/18)

Douglas T. Dieterich, MD, FACP
Professor of Medicine
Mount Sinai School of Medicine
New York, New York

Dr Dieterich has served as a consultant or scientific advisor for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Merck & Co, Inc, and Janssen Therapeutics. He has received grants or research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, and Janssen Therapeutics. (Updated 04/07/14)

Charles W. Flexner, MD
Professor of Medicine, Pharmacology, and International Health
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Dr Flexner has served as a consultant to Cipla Pharmaceuticals, Janssen Pharmaceuticals, Merck & Co, Inc, Mylan Pharmaceuticals, and ViiV Healthcare, and received research grant support paid to his institution from Gilead Sciences, Inc. (Updated 09/27/18)

Marshall J. Glesby, MD, PhD
Professor of Medicine and Healthcare Policy and Research
Weill Cornell Medicine
New York, New York

Dr Glesby has received research support paid to his institution from Gilead Sciences, Inc. (Updated 09/10/18)

Arthur Y. Kim, MD
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr Kim has no relevant financial affiliations to disclose. (Updated 10/19/18)

Susanna Naggie, MD, MHS
Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina

Dr Naggie has received research support from AbbVie, Gilead Sciences, Inc, Janssen Therapeutics, and Tacere; served on an events adjudication committee for Bristol-Myers Squibb; and served as scientific advisor to BioMarin and Vir Biotechnology. (Updated 01/01/19)

Marion G. Peters, MD
Professor of Medicine
University of California San Francisco
San Francisco, California

Dr Peters has served as an advisor to Abbott. Her spouse is employed by Hoffman-La Roche (Updated 04/17/19)

Michael S. Saag, MD
Professor of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 03/29/19)

Robert T. Schooley, MD
Professor of Medicine
University of California San Diego
La Jolla, California

Dr Schooley has served as a consultant to CytoDyn and Gilead Sciences, Inc. He has received grant support from Gilead Sciences, Inc, and holds stock or stock options in Antiva Biosciences and CytoDyn. His spouse serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare and has received research grants awarded to her institution from Gilead Sciences, Inc. (Updated 04/02/19)

Kenneth E. Sherman, MD, PhD
Gould Professor of Medicine
University of Cincinnati College of Medicine
Cincinnati, Ohio

Dr Sherman has received grant support or contracts awarded to his institution from AbbVie, Gilead Sciences, Inc, Intercept Pharmaceuticals, Inc, MedImmune, and Merck & Co, Inc; served as an advisor or consultant to UniQure and Inovio Pharmaceuticals; and served on data and safety monitoring boards for Watermark and Medpace. (Updated 04/29/19)

David L. Thomas, MD, MPH
Professor of Medicine
The Johns Hopkins Medical Institutions
Baltimore, Maryland

Dr Thomas has no relevant financial affiliations to disclose. (Updated 02/14/19)

David L. Wyles, MD
Chief, Division of Infectious Diseases
Denver Health Medical Center
Denver, Colorado

Dr Wyles has received grant support awarded to his institution from Gilead Sciences, Inc. (Updated 03/28/19)